A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months
Sponsor: BioMarin Pharmaceutical
Listed as NCT03583697, this PHASE2 trial focuses on Achondroplasia and remains completed. Sponsored by BioMarin Pharmaceutical, it has been updated 14 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jan 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2020 — Aug 2020 [monthly]
Enrolling By Invitation PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2019 — Dec 2019 [monthly]
Enrolling By Invitation PHASE2
-
Mar 2019 — Jun 2019 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Enrolling By Invitation PHASE2
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioMarin Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .